Trulieve Cannabis Corp. (TRLV) Key Metrics
TRLV valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.93B
- Enterprise value
- $2.65B
- P/E (TTM)
- —
- Forward P/E
- 22.9
- PEG ratio
- —
- Price / sales
- 1.7
- Price / book
- 3.1
- EV / EBITDA
- 6.1
- Dividend yield
- —
- Beta
- 1.80
TRLV key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTRLV returns How much profit the business earns on the capital it uses.
TRLV per-share figures Results divided by the shares outstanding at year-end.
TRLV financial health Debt, liquidity and how easily interest is covered.
TRLV efficiency & capital use Working capital cycle and where the cash goes.
TRLV returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TRLV debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TRLV cash returned to shareholders
TRLV key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Per share | ||||
| Revenue per share | $6.17 | $6.21 | $6.06 | $6.55 |
| Earnings per share | −$0.61 | −$0.81 | −$2.83 | −$1.32 |
| Operating cash flow per share | $1.43 | $1.42 | $1.08 | $0.12 |
| Free cash flow per share | $1.11 | $0.65 | $0.81 | −$0.92 |
| Cash per share | $1.34 | $1.25 | $1.08 | $1.11 |
| Book value per share | $6.07 | $6.60 | $7.60 | $10.38 |
| Tangible book value per share | −$0.63 | −$0.43 | $0.07 | $0.83 |
| Dividends per share | — | — | $0.00 | $0.00 |
| Capex per share | $0.32 | $0.77 | $0.27 | $1.04 |
| Debt per share | $2.95 | $2.50 | $2.57 | $3.42 |
| Shares outstanding | 191.3M | 191.0M | 186.2M | 186.0M |
| Change in shares outstanding | +0.2% | +2.6% | +0.1% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −9.6% | −11.6% | −31.5% | −12.7% |
| Return on invested capital (ROIC) | 5.0% | 4.6% | 3.6% | 4.2% |
| Return on assets (ROA) | −4.2% | −5.5% | −17.2% | −7.2% |
| Return on tangible assets | −8.2% | −10.2% | −39.7% | −15.2% |
| Free cash flow margin | 18.0% | 10.4% | 13.4% | −14.0% |
| Financial health | ||||
| Total debt | $563.6M | $476.8M | $479.1M | $635.9M |
| Cash & short-term investments | $255.5M | $238.8M | $201.4M | $207.2M |
| Net debt | $308.1M | $238.0M | $277.7M | $428.7M |
| Debt / equity | 0.49 | 0.38 | 0.34 | 0.33 |
| Debt / assets | 0.21 | 0.17 | 0.18 | 0.19 |
| Net debt / EBITDA | 0.94 | 0.88 | — | 1.79 |
| Current ratio | 4.43 | 4.37 | 4.16 | 2.82 |
| Quick ratio | 2.52 | 2.69 | 2.30 | 1.51 |
| Interest coverage | 2.3 | 1.5 | 1.1 | 1.7 |
| Working capital | $435.8M | $466.1M | $362.5M | $383.2M |
| Invested capital | $1.47B | $1.50B | $1.69B | $2.36B |
| Tangible asset value | −$139.3M | −$94.4M | $7.5M | $151.4M |
| Net current asset value | −$990.4M | −$1.02B | −$843.1M | −$879.2M |
| Graham net-net per share | −$6.07 | −$6.60 | −$5.41 | −$6.03 |
| Capital allocation | ||||
| Dividends paid | — | — | $50,000 | $50,000 |
| Dividends + buybacks / free cash flow | — | — | 0.0% | — |
| Capex / revenue | 5.1% | 12.4% | 4.5% | 15.9% |
| Capex / operating cash flow | 22.2% | 54.4% | 25.2% | 839.1% |
| Capex / depreciation | 0.35 | 0.89 | 0.30 | 1.04 |
| Stock-based compensation / revenue | 1.7% | 1.7% | 0.9% | 1.5% |
| SG&A / revenue | 37.7% | 43.0% | 34.2% | 36.7% |
| Efficiency | ||||
| Days sales outstanding | 4.4 | 2.3 | 2.1 | 1.9 |
| Days of inventory on hand | 183.9 | 172.3 | 165.3 | 190.7 |
| Days payables outstanding | 18.3 | 18.8 | 14.9 | 10.9 |
| Cash conversion cycle (days) | 170.1 | 155.8 | 152.5 | 181.8 |
| Receivables turnover | 82.92 | 158.29 | 170.96 | 187.22 |
| Payables turnover | 20.00 | 19.42 | 24.51 | 33.37 |
| Inventory turnover | 1.98 | 2.12 | 2.21 | 1.91 |
| Asset turnover | 0.42 | 0.42 | 0.37 | 0.36 |
| Average receivables | $14.2M | $7.5M | $6.6M | $6.5M |
| Average payables | $23.5M | $24.2M | $22.1M | $15.9M |
| Average inventory | $236.8M | $222.2M | $244.8M | $276.5M |
| Intangibles / total assets | 47.6% | 46.8% | 51.3% | 52.2% |
Computed from TRLV's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TRLV valuation and financial ratios
Trulieve Cannabis earned a return on equity of −9.6% and a return on invested capital of 5.0% in fiscal 2025. It ended the year with $563.6 million of debt and $255.5 million in cash and short-term investments, net debt of $308.1 million.
See the TRLV income statement, the TRLV chart for price history, or the TRLV stock overview for the latest quote and news.
TRLV key metrics FAQ
What is Trulieve Cannabis's return on equity?
Trulieve Cannabis's return on equity (ROE) was −9.6% in fiscal 2025: net income of -$116.4 million on average shareholders' equity of $1.2 billion.
What is Trulieve Cannabis's ROIC?
Trulieve Cannabis's return on invested capital was 5.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Trulieve Cannabis have?
Trulieve Cannabis had total debt of $563.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.49 and $308.1 million of net debt (0.94 times EBITDA).
What is Trulieve Cannabis's current ratio?
Trulieve Cannabis's current ratio was 4.43 at the end of fiscal 2025: current assets were 4.43 times current liabilities.